LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 41 filers reported holding LYRA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,904,641 | +21.9% | 1,254,384 | +28.2% | 0.59% | -8.0% |
| Q2 2023 | $4,022,153 | +465.4% | 978,626 | +184.7% | 0.64% | +298.1% |
| Q1 2023 | $711,427 | -34.1% | 343,685 | 0.0% | 0.16% | -38.1% |
| Q4 2022 | $1,079,171 | -37.3% | 343,685 | 0.0% | 0.26% | -24.2% |
| Q3 2022 | $1,722,000 | -12.3% | 343,685 | -1.1% | 0.34% | -4.2% |
| Q2 2022 | $1,963,000 | +15.6% | 347,338 | -17.8% | 0.36% | +60.5% |
| Q1 2022 | $1,698,000 | -1.2% | 422,338 | +7.0% | 0.22% | -12.9% |
| Q4 2021 | $1,719,000 | -53.4% | 394,536 | -2.2% | 0.26% | -1.5% |
| Q3 2021 | $3,688,000 | -26.5% | 403,450 | -35.4% | 0.26% | -36.0% |
| Q2 2021 | $5,017,000 | -44.6% | 624,684 | -20.0% | 0.41% | +33.1% |
| Q1 2021 | $9,048,000 | -2.7% | 780,728 | -4.2% | 0.30% | -25.6% |
| Q4 2020 | $9,295,000 | +114.3% | 815,364 | +110.2% | 0.41% | +30.6% |
| Q3 2020 | $4,338,000 | – | 387,939 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,777,251 | $5,580,568 | 1.20% |
| Perceptive Advisors | 9,146,730 | $28,720,732 | 0.81% |
| VR Adviser, LLC | 924,170 | $2,901,894 | 0.49% |
| Nantahala Capital Management | 2,220,830 | $6,973,406 | 0.45% |
| PURA VIDA INVESTMENTS, LLC | 2,157,298 | $6,773,916 | 0.35% |
| Soleus Capital Management, L.P. | 592,417 | $1,860,189 | 0.27% |
| Ikarian Capital, LLC | 343,685 | $1,079,171 | 0.26% |
| Clearline Capital LP | 119,128 | $374,062 | 0.07% |
| Anson Funds Management LP | 39,127 | $122,859 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 146,800 | $460,952 | 0.01% |